Merck, 116812-10MG, Adenosine 3′,5′-cyclic Monophosphate, 8-(4-Chlorophenylthio)-, Sodium Salt

General description
Cell-permeable cAMP analog that activates both protein kinase A and protein kinase G. Induces the guanine-nucleotide-exchange factor activity of EGFI, also known as Epac (exchange protein directly activated by cAMP), and EGFII towards Rap1 both in vivo and in vitro. Also acts as a potent inhibitor of cGMP specific phosphodiesterase (IC₅₀ = 900 nM). Also inhibits cAMP-specific phosphodiesterases at much higher concentrations (IC₅₀ = 25 µM).
Biochem/physiol Actions
Product does not compete with ATP.
Reversible: no
Cell permeable: yes
Primary Target
Protein kinase A and protein kinase G
Target IC₅₀: 900 nM against cGMP-specific phosphodiesterase
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C
Other Notes
de Rooij, J., et al. 1998. Nature.396, 474.
Kawasaki, H., et al. 1998. Science.282, 2275.
Moed, P.J., et al. 1993. Comp. Biochem. Physiol.105A, 711.
Connolly, B.J., et al. 1992. Biochem. Pharmacol.44, 2303.
Phillips, M.E., and Taylor, A. 1992. J. Physiol.456, 591.
Shipston, M.J., and Antoni, F.A. 1992. Endocrinology130, 2213.
Datta, R., et al. 1991. Blood78, 83.
Peters, D.J.M., et al. 1991. Proc. Natl. Acad. Sci. USA88, 9219.
Sandberg, M., et al. 1991. Biochem. J.279, 521.
Unterman, T.G., et al. 1991. Endocrinology128, 2693.
Xu, H., et al. 1989. Brain Res.504, 36.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)